|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
+1.69% | -26.73% |
Investment objective
The Range Cancer Therapeutics ETF (Nasdaq: CNCR) is purpose-built to provide exposure to a wide range of cancer therapeutic modalities. Despite a significant retrenchment in biotech valuations, we believe cancer remains one of the most vexing public health issues and will remain at the forefront of investment and technological innovation. Owning a broad basket which is equal weight provides the CNCR ETF exposure to nearly the entire lifecycle of drug development and distribution.
Off-Hours Price |
Change |
YTD change |
Weight | ||
|---|---|---|---|---|---|
 | 2.215USD | +1.61% | -59.12% | - | |
| 17.72USD | +2.55% | +70.29% | - | |
| 21.53USD | +0.19% | +131.01% | - | |
| 8.475USD | +3.35% | -28.33% | - | |
| 15.12USD | -1.72% | -1.37% | - | |
| 1.605USD | +1.58% | -20.85% | - | |
| 4.280USD | +1.66% | -39.90% | - | |
| 97.57USD | +3.89% | +2.22% | - | |
| 1.475USD | +8.46% | +17.34% | - | |
In partnership with
Description
| US26922A8264 |
|---|
- Stock Market
- ETF
- CNCR ETF
Select your edition
All financial news and data tailored to specific country editions
